Biodegradable Compacted Rod Formulations for Sustained Drug Release
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current buprenorphine formulations for opioid use disorder (OUD) treatment face challenges such as high initial burst release, poor drug loading, and short duration of action, leading to low treatment retention and potential misuse, with existing microparticle formulations being difficult to scale and costly.
Innovation Solution
Development of biodegradable, compacted single-rod formulations using polymers like PLGA, which are free of pores to achieve controlled and sustained release of buprenorphine for extended periods, overcoming the limitations of microparticle formulations by allowing higher drug loading and longer therapy duration with simpler processing steps.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If microparticle formulations are used to achieve controlled release, then drug release is extended, but manufacturing complexity increases and scalability decreases
Solution Approach 1:
The invention divides the drug delivery system into discrete microparticles with controlled size distributions (e.g., 10-50 μm, 50-100 μm ranges) that can be independently manufactured and combined. This segmentation enables scalable production through standardized processes while achieving extended release durations of 1-6 months through controlled polymer degradation
Solution Approach 2:
The invention changes physical parameters including polymer composition (PLGA ratios from 75:25 to 50:50), microparticle size (10-200 μm ranges), and drug loading concentrations (10-50% w/w) to optimize the balance between release duration and manufacturing feasibility. These parameter adjustments enable controlled release without requiring complex manufacturing processes
2Quantity of substance
If higher drug loading is achieved in formulations, then treatment duration is extended, but initial burst release increases
Solution Approach 1:
The invention creates local quality variations within microparticles through core-shell structures and non-uniform drug distribution patterns. Drug is concentrated in specific regions (core or shell) rather than uniformly distributed, with local drug loading varying from 10-30% in different zones. This local heterogeneity enables high overall drug loading (10-50% w/w) while controlling burst release through spatial separation of drug reservoirs
Solution Approach 2:
The invention uses composite material systems combining biodegradable polymers (PLGA, PLA, PCL) with varying ratios and molecular weights. The composite structure includes polymer matrices with different degradation rates (from 1-6 months) that control drug release kinetics. This composite approach enables high drug loading capacities while the polymer network structure prevents premature drug release
3Reliability
If biodegradable polymers are used for sustained release, then treatment retention improves, but manufacturing cost increases
Solution Approach 1:
The invention employs biodegradable polymers that naturally degrade over 1-6 months, eliminating the need for retrieval surgery. The polymers (PLGA, PLA, PCL) are cost-effective materials that can be processed through simple methods like solvent evaporation and extrusion. This disposable approach improves treatment retention by ensuring complete drug delivery before natural degradation, avoiding additional medical intervention costs
Solution Approach 2:
The biodegradable polymer matrix performs self-service by automatically degrading and releasing drug over time without external intervention. The polymer's inherent degradation properties (hydrolysis of ester bonds in PLGA/PLA) provide sustained release kinetics, eliminating the need for complex controlled-release mechanisms or retrieval procedures. This self-degrading capability reduces manufacturing complexity and overall treatment cost
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compacted rod formulations provide a high drug load with controlled release kinetics, extending treatment duration beyond 3 months, improving treatment retention and reducing the risk of misuse, while being scalable and cost-effective.
Implementation Method 1
biodegradable polymers, such as poly(lactide-co-glycolide) (PLGA)
Implementation Method 2
The increased microstructure density of the compacted rods allows slower water uptake kinetics, ultimately resulting in slower drug release
Data Source
AI summary
The present invention generally relates to formulations comprising a drug and biodegradable polymers that are compacted mechanically from a physical mixture to disrupt interconnected open channels for substantially longer drug release than non-compacted counterpart formulations and methods of use and manufacture thereof.